These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9543445)

  • 21. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
    Haubrich R; Thompson M; Schooley R; Lang W; Stein A; Sereni D; van der Ende ME; Antunes F; Richman D; Pagano G; Kahl L; Fetter A; Brown DJ; Clumeck N
    AIDS; 1999 Dec; 13(17):2411-20. PubMed ID: 10597783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
    Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
    Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR
    J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
    Lambert JS; Viscidi R; Walker MC; Clayman B; Winget M; Wolff M; Schwartz DH
    Clin Diagn Lab Immunol; 1997 May; 4(3):302-8. PubMed ID: 9144368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
    Montaner JS; DeMasi R; Hill AM
    AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine.
    Cox JH; Garner RP; Redfield RR; Aronson NE; Davis C; Ruiz N; Birx DL
    AIDS Res Hum Retroviruses; 1999 Jun; 15(9):847-54. PubMed ID: 10381173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunisation with gp160 in HIV-1 infection.
    Fiala C; Stewart GT
    Lancet; 1999 Sep; 354(9182):948; author reply 949. PubMed ID: 10489976
    [No Abstract]   [Full Text] [Related]  

  • 30. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apoptosis in asymptomatic HIV-1 seropositives immunized with HIV-1 env glycoprotein (gp160): effects of administration of Zidovudine in vivo and interleukin-2 in vitro.
    Pierdominici M; Mollicone B; Ricci G; Oliva A; D'Offizi G; Giovannetti A; Aiuti F; Pandolfi F
    Vaccine; 1998 Apr; 16(7):715-21. PubMed ID: 9562691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization.
    Gudmundsdotter L; Boström AC; Burton C; Rosignoli G; Sandström E; Hejdeman B; Wahren B; Imami N; Gotch F
    Vaccine; 2008 Sep; 26(40):5107-10. PubMed ID: 18455841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.
    Bratt G; Leandersson AC; Albert J; Sandström E; Wahren B
    AIDS; 1998 May; 12(7):729-36. PubMed ID: 9619804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.
    Ratto-Kim S; Garner RP; Kim JH; Jagodzinski LL; Michael NL; Paris R; Redfield RR; Birx DL
    J Infect Dis; 2004 Jun; 189(11):1988-95. PubMed ID: 15143464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological aspects of patients with HIV-1 disease following immunization with recombinant gp160 (VaxSyn).
    Guerra E; Ricci G; Carlesimo M; Varani AR; Pontesilli O; Scala E; Mezzaroma I; Pierdominici ; Pandolfi F; Antinori A; De Luca A; Murri R; Ammassari A; Ortona L; Aiuti F
    Antibiot Chemother (1971); 1996; 48():147-54. PubMed ID: 8726519
    [No Abstract]   [Full Text] [Related]  

  • 37. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization.
    Robbins GK; Addo MM; Troung H; Rathod A; Habeeb K; Davis B; Heller H; Basgoz N; Walker BD; Rosenberg ES
    AIDS; 2003 May; 17(8):1121-6. PubMed ID: 12819512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
    Kundu SK; Katzenstein D; Moses LE; Merigan TC
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
    Autran B; Murphy RL; Costagliola D; Tubiana R; Clotet B; Gatell J; Staszewski S; Wincker N; Assoumou L; El-Habib R; Calvez V; Walker B; Katlama C;
    AIDS; 2008 Jul; 22(11):1313-22. PubMed ID: 18580611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.